Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Moderate-to-Severe Atopic Dermatitis: full-pipeline trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Moderate-to-Severe Atopic Dermatitis: 5 US clinical trials tracked, none currently recruiting.
Moderate-to-Severe Atopic Dermatitis is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Galderma R&D, running 2 of these trials.
Enrollment posture brief
Registry condition moderate-to-severe-atopic-dermatitis
OPEN 0 | RECR 0% | LATE 3 | EARLY 2 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Moderate-to-Severe Atopic Dermatitis has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Moderate-to-Severe Atopic Dermatitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Moderate-to-Severe Atopic Dermatitis is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Moderate-to-Severe Atopic Dermatitis research.
Galderma R&D accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Moderate-to-Severe Atopic Dermatitis enrolment sits around 251 participants.
Median target enrolment is 251 among the 5 trials that report a genuine target (sentinel values excluded). 0 of those (0%) plan for fewer than 100 participants.
-
Moderate-to-Severe Atopic Dermatitis research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Galderma R&D
NCT03989206
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics
NCT06136741
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Regeneron Pharmaceuticals
NCT03054428
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Amgen
NCT05899816
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
Galderma R&D
NCT04921345
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Moderate-to-Severe Atopic Dermatitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Moderate-to-Severe Atopic Dermatitis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Moderate-to-Severe Atopic Dermatitis page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Moderate-to-Severe Atopic Dermatitis trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Galderma R&D sponsors the most Moderate-to-Severe Atopic Dermatitis trials on record, review their full trial history before evaluating a specific study. See Galderma R&D's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Moderate-to-Severe Atopic Dermatitis condition card totals 5 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.